Cumberland Pharmaceuticals Inc Stock Price, News & Analysis

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported a strong third quarter in 2022, with revenues of $11.4 million, reflecting a 41% increase from the previous year. Year-to-date revenues reached $33 million, a 19% increase compared to 2021. The company attributed growth to initial sales from its newly acquired product, Sancuso. Operating expenses rose to $11.7 million, resulting in a net loss of $0.4 million, improved from last year's loss of $1.1 million. Cash flow from operations increased by 28% to $5.6 million. Total assets stood at $91 million.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) will announce its third quarter 2022 financial results after market close on Nov. 8, 2022. The company aims to provide updates during a conference call at 4:30 p.m. Eastern Time the same day. Cumberland, based in Nashville, focuses on developing prescription brands in acute care and other segments. Its portfolio includes FDA-approved drugs such as Acetadote and Caldolor, among others. The company also has ongoing Phase II clinical programs for its ifetroban candidate addressing various serious health conditions.

Cumberland Pharmaceuticals (NASDAQ: CPIX) has relocated its headquarters to the Broadwest campus in Nashville, Tennessee. This move accommodates recent growth, increasing staff to over 100 employees. The Broadwest complex features a 21-story office tower and various amenities that enhance the company's operational capabilities. CEO A.J. Kazimi highlighted Nashville's role as a healthcare hub, which supports the company's FDA-approved brands and pipeline for future medicines. The location near Vanderbilt University Medical Center will foster further collaborations.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported a 14% revenue increase to $10.3 million for Q2 2022, with year-to-date gross revenue rising 10% to $21.5 million compared to 2021. Cash flow from operations reached $2.2 million, and the company holds total assets of $93 million against liabilities of $53 million. Key highlights include the acquisition of Sancuso® and its national co-promotion with Verity Pharmaceuticals. Additionally, Cumberland is advancing multiple Phase II clinical studies for its product candidate ifetroban.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) has released its 2021 Sustainability Report, showcasing significant achievements in environmental, social, and governance initiatives. The company delivered 2.43 million patient doses and disposed of 6,200 pounds of expired goods without any product recalls or FDA-related issues. Cumberland invested $4,000 per employee in training, while maintaining a workforce composed of 44% women and 15% minorities. Additionally, the company supported patients by covering up to 60% of prescription costs for gastrointestinal products.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) will announce its second quarter 2022 financial results on August 9, 2022, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss the results. The company focuses on developing and commercializing prescription brands for hospital acute care, gastroenterology, rheumatology, and oncology. Its FDA-approved products include Acetadote, Caldolor, and Kristalose. Cumberland is also advancing Phase II clinical programs for its ifetroban candidate, targeting conditions like cardiomyopathy and systemic sclerosis.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced the appointment of Martin Brown Jr. to its Board of Directors as of July 19, 2022. Brown, with nearly 30 years of legal experience, previously served on the Board of Brown-Forman Corporation and currently practices at Adams and Reese LLP. His background in health care and corporate law is expected to enhance Cumberland's mission to address unmet medical needs. Brown holds degrees from Yale University and Vanderbilt University.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported financial results for Q1 2022, with net revenues of $11.2 million, a 6% increase from the prior year. Adjusted earnings were $0.5 million or $0.03 per share. The company had total assets of $96.7 million and total liabilities of $55.9 million, resulting in shareholders' equity of $41.0 million. Cumberland acquired the oncology-supportive drug Sancuso and formed a new sales division. Additionally, partnerships were announced for Vibativ in the Middle East and Puerto Rico, expanding market reach.

Cumberland Pharmaceuticals Inc. (CPIX) announced a national co-promotion agreement with Verity Pharmaceuticals to promote Sancuso, the first FDA-approved patch for preventing chemotherapy-induced nausea and vomiting (CINV). Sancuso releases granisetron through the skin, effective for up to five days when applied before chemotherapy. Verity will leverage its oncology sales organization to enhance Sancuso's market reach following Cumberland's earlier acquisition of its U.S. rights. This partnership aims to expand patient access to Sancuso through shared marketing and sales efforts.